ConforMIS Inc (NASDAQ:CFMS) has received an average recommendation of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.70.

Several analysts have commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $4.00 price objective on shares of ConforMIS in a research report on Wednesday, January 10th. Zacks Investment Research lowered shares of ConforMIS from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. Finally, JPMorgan Chase & Co. lowered shares of ConforMIS from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd.

Shares of ConforMIS (CFMS) opened at $2.33 on Friday. The company has a market cap of $110.06, a PE ratio of -1.74 and a beta of 2.21. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.19 and a quick ratio of 5.38. ConforMIS has a 12-month low of $2.21 and a 12-month high of $8.61.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. The business had revenue of $18.40 million for the quarter, compared to analyst estimates of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. equities analysts forecast that ConforMIS will post -1.27 EPS for the current year.

In other news, insider David Cerveny sold 16,392 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total value of $51,962.64. Following the completion of the transaction, the insider now owns 151,408 shares in the company, valued at $479,963.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Daniel Steines sold 15,485 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $3.15, for a total transaction of $48,777.75. Following the completion of the transaction, the chief technology officer now owns 254,652 shares of the company’s stock, valued at approximately $802,153.80. The disclosure for this sale can be found here. Insiders sold 83,248 shares of company stock valued at $235,021 in the last quarter. Corporate insiders own 9.55% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of CFMS. Stonebridge Capital Management Inc. purchased a new position in shares of ConforMIS in the third quarter worth about $130,000. The Manufacturers Life Insurance Company increased its stake in shares of ConforMIS by 21.4% in the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 6,535 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of ConforMIS by 31.1% in the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 9,500 shares in the last quarter. Rhumbline Advisers increased its stake in shares of ConforMIS by 21.8% in the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 8,017 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of ConforMIS by 59.2% in the second quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock worth $230,000 after purchasing an additional 19,900 shares in the last quarter. Hedge funds and other institutional investors own 35.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ConforMIS Inc (CFMS) Receives Average Recommendation of “Hold” from Brokerages” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/conformis-inc-cfms-receives-average-recommendation-of-hold-from-brokerages/1813518.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.